Vir Biotechnology Inc (VIR)
9.72
-0.21
(-2.11%)
USD |
NASDAQ |
May 17, 16:00
9.72
0.00 (0.00%)
Pre-Market: 20:00
Vir Biotechnology Research and Development Expense (Quarterly): 100.12M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 100.12M |
| December 31, 2023 | 111.92M |
| September 30, 2023 | 148.25M |
| June 30, 2023 | 171.86M |
| March 31, 2023 | 157.64M |
| December 31, 2022 | 155.17M |
| September 30, 2022 | 114.17M |
| June 30, 2022 | 115.08M |
| March 31, 2022 | 90.23M |
| December 31, 2021 | 128.34M |
| September 30, 2021 | 98.67M |
| June 30, 2021 | 86.13M |
| Date | Value |
|---|---|
| March 31, 2021 | 134.87M |
| December 31, 2020 | 87.10M |
| September 30, 2020 | 70.68M |
| June 30, 2020 | 79.65M |
| March 31, 2020 | 64.98M |
| December 31, 2019 | 52.93M |
| September 30, 2019 | 39.86M |
| June 30, 2019 | 29.80M |
| March 31, 2019 | 25.87M |
| December 31, 2018 | 21.97M |
| September 30, 2018 | 29.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
29.80M
Minimum
Jun 2019
171.86M
Maximum
Jun 2023
101.87M
Average
99.40M
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 789.10M |
| SeaStar Medical Holding Corp | 1.075M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 1.535M |